Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-
TMA) is a severe and potentially life-threatening complication. HSCT-TMA is often …

Over the last decade there have been numerous advances in both the diagnosis and
treatment of transplant‐associated thrombotic microangiopathy (TA‐TMA). These are largely …

Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a common, severe
complication of allogeneic hematopoietic cellular therapy (HCT). Even when treated in many …

Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) detected in the liver
has been considered a severe complication of hematopoietic stem cell transplantation …

Gene therapy advances offer great hope to previously uncurable disorders but come with a
steep learning curve to assure safety and therapeutic success. Thrombotic microangiopathy …

TCRαβ/CD19 cell depletion is a promising graft manipulation technique frequently used in
the context of human leukocyte antigen (HLA)–haploidentical hematopoietic stem cell …

Transplant-associated thrombotic microangiopathy (TA-TMA) is an endotheliopathy
complicating up to 30% of allogeneic hematopoietic stem cell transplants (alloHSCT) …

Neurologic complications (NCs), especially those of the central nervous system (CNS),
represent a severe complication after allogeneic stem cell transplantation (allo-HSCT) and …

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory
syndrome that is most commonly treated with etoposide and dexamethasone. This standard …

High titer of donor-specific antibodies (DSAs) increases the risk of graft rejection after
mismatched related hematopoietic cell transplantation (HCT). There are no data regarding …